COVID-19与运动员心脏:病理、风险与重返赛场的崭新视角
本文关注COVID-19感染后运动员的心脏损伤(包括心肌炎)风险,指出住院患者中心脏损伤常见且预后不良,而无症状或轻症感染是否也导致心脏损伤尚不明确。美国心脏病学会运动心脏病学分会曾发布保守的重返赛场共识建议,但新观察数据提示无症状和轻症感染者也可能出现心肌损伤,目前正通过多中心注册研究收集数据以明确病理患病率和风险分层效果。
要点
- 住院COVID-19患者中心脏损伤常见且与不良预后相关。
- 无症状或轻症COVID-19感染是否引起心肌炎等心脏损伤尚不确定。
- 运动员COVID-19后重返赛场需心血管风险分层,但最佳策略待明确。
核心结论
- COVID-19住院患者常见心脏损伤且预后不良,但无症状或轻症感染是否也导致心脏损伤尚不明确。
- 运动员COVID-19相关心脏病理(包括心肌炎)可能发生在无症状和轻症感染中,增加运动时心源性猝死风险。
- 目前缺乏确定性数据,运动员COVID-19后心血管风险分层的最佳方法仍存在不确定性。
研究设计与样本
- 本文为综述性报告,基于现有观察性数据和专家共识,旨在解答运动员COVID-19心脏病理的常见问题。
主要发现
- 住院COVID-19患者中心脏损伤常见,且与不良预后相关。
- 新出现的观察性数据和公开报道提示,无症状和轻症COVID-19感染中也可能发生心肌损伤。
- 美国心脏病学会运动心脏病学分会曾发布经验性共识建议,对康复的竞技运动员采取保守的重返赛场策略,包括心血管风险分层。
- 目前正在收集多中心注册数据,以确定运动员COVID-19相关心脏病理的患病率、严重程度和临床相关性。
关键数值与推荐
- 美国心脏病学会运动心脏病学分会建议对COVID-19康复的竞技运动员进行心血管风险分层并采取保守的重返赛场策略。
临床怎么用
- 对COVID-19康复的竞技运动员应进行心血管风险分层,包括评估心肌损伤证据。
- 在缺乏确定性数据时,应采取保守的重返赛场策略,尤其关注无症状和轻症感染运动员。
- 临床医生应关注正在进行的多中心注册研究结果,以指导风险分层和重返赛场决策。
局限性
- 关于无症状和轻症COVID-19感染是否引起心脏损伤的数据尚不明确。
- 缺乏确定性数据来确定运动员COVID-19后心血管风险分层的最佳方法。
- 多中心注册研究数据仍在收集中,尚未得出结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardiac injury with attendant negative prognostic implications is common among patients hospitalized with coronavirus disease 2019 (COVID-19) infection. Whether cardiac injury, including myocarditis, also occurs with asymptomatic or mild-severity COVID-19 infection is uncertain. There is an ongoing concern about COVID-19-associated cardiac pathology among athletes because myocarditis is an important cause of sudden cardiac death during exercise. OBSERVATIONS: Prior to relaxation of stay-at-home orders in the US, the American College of Cardiology's Sports and Exercise Cardiology Section endorsed empirical consensus recommendations advising a conservative return-to-play approach, including cardiac risk stratification, for athletes in competitive sports who have recovered from COVID-19. Emerging observational data coupled with widely publicized reports of athletes in competitive sports with reported COVID-19-associated cardiac pathology suggest that myocardial injury may occur in cases of COVID-19 that are asymptomatic and of mild severity. In the absence of definitive data, there is ongoing uncertainty about the optimal approach to cardiovascular risk stratification of athletes in competitive sports following COVID-19 infection. CONCLUSIONS AND RELEVANCE: This report was designed to address the most common questions regarding COVID-19 and cardiac pathology in athletes in competitive sports, including the extension of return-to-play considerations to discrete populations of athletes not addressed in prior recommendations. Multicenter registry data documenting cardiovascular outcomes among athletes in competitive sports who have recovered from COVID-19 are currently being collected to determine the prevalence, severity, and clinical relevance of COVID-19-associated cardiac pathology and efficacy of targeted cardiovascular risk stratification. While we await these critical data, early experiences in the clinical oversight of athletes following COVID-19 infection provide an opportunity to address key areas of uncertainty relevant to cardiology and sports medicine practitioners.
引用
- Kim JH, Levine BD, Phelan D, et al. Coronavirus Disease 2019 and the Athletic Heart: Emerging Perspectives on Pathology, Risks, and Return to Play. JAMA Cardiol. 2021. PMID: 33104154. doi:10.1001/jamacardio.2020.5890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。